196 related articles for article (PubMed ID: 35523116)
1. The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: A randomized placebo-controlled trial.
Benjawan S; Nimitphong H; Tragulpiankit P; Musigavong O; Prathanturarug S; Pathomwichaiwat T
Phytomedicine; 2022 Jul; 101():154115. PubMed ID: 35523116
[TBL] [Abstract][Full Text] [Related]
2. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
3. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Yigu® versus Aclasta® in Chinese postmenopausal women with osteoporosis: a multicenter prospective study.
Li M; Cheng Q; Huo YN; Chao AJ; He L; Xue QY; Xu J; Yan SG; Jin H; Zhang ZL; Lin JH; Jin XL; Xu YJ; Liu F; Xia WB
Arch Osteoporos; 2022 Jan; 17(1):14. PubMed ID: 35020038
[TBL] [Abstract][Full Text] [Related]
5. Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia.
Naylor KE; Jacques RM; Peel NF; Gossiel F; Eastell R
Osteoporos Int; 2016 Aug; 27(8):2585-92. PubMed ID: 27026335
[TBL] [Abstract][Full Text] [Related]
6. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
[TBL] [Abstract][Full Text] [Related]
7. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
[TBL] [Abstract][Full Text] [Related]
8. Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial.
Pingali U; Nutalapati C
Phytomedicine; 2022 Oct; 105():154334. PubMed ID: 35933897
[TBL] [Abstract][Full Text] [Related]
9. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
10. POTASSIUM CITRATE DECREASES BONE RESORPTION IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA: A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL.
Gregory NS; Kumar R; Stein EM; Alexander E; Christos P; Bockman RS; Rodman JS
Endocr Pract; 2015 Dec; 21(12):1380-6. PubMed ID: 26401577
[TBL] [Abstract][Full Text] [Related]
11. A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.
Zhang H; Gu JM; Chao AJ; Cheng Q; Teng DH; Yu JM; Wang BW; Huo YN; Mao L; Zhang Q; Yang H; Yan SG; Zhang KQ; Zhao XL; Lin H; Pei Y; Yuan Z; Dai RC; He L; Chen L; Su YF; Deng ZL; You L; Ban B; Zhu M; Cao YL; Zhu YK; Li ZJ; Zhang Z; Yi CQ; Lu YB; Wang G; Han CC; Wang ZJ; Li XX; Zhang ZL
Acta Pharmacol Sin; 2023 Feb; 44(2):446-453. PubMed ID: 35896694
[TBL] [Abstract][Full Text] [Related]
12. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
[TBL] [Abstract][Full Text] [Related]
13. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial.
Cheung AM; Tile L; Lee Y; Tomlinson G; Hawker G; Scher J; Hu H; Vieth R; Thompson L; Jamal S; Josse R
PLoS Med; 2008 Oct; 5(10):e196. PubMed ID: 18922041
[TBL] [Abstract][Full Text] [Related]
14. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial.
Lambert MNT; Thybo CB; Lykkeboe S; Rasmussen LM; Frette X; Christensen LP; Jeppesen PB
Am J Clin Nutr; 2017 Sep; 106(3):909-920. PubMed ID: 28768651
[No Abstract] [Full Text] [Related]
15. Declining serum bone turnover markers are associated with the short-term positive change of lumbar spine bone mineral density in postmenopausal women.
Zhao S; Mo X; Wen Z; Liu M; Chen Z; Lin W; Huang Z; Chen B
Menopause; 2022 Jan; 29(3):335-343. PubMed ID: 35102102
[TBL] [Abstract][Full Text] [Related]
16. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
[TBL] [Abstract][Full Text] [Related]
17. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
[TBL] [Abstract][Full Text] [Related]
18. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial.
Piriyakhuntorn P; Tantiworawit A; Phimphilai M; Srichairatanakool S; Teeyasoontranon W; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Fanhchaksai K; Charoenkwan P
Front Endocrinol (Lausanne); 2023; 14():1178761. PubMed ID: 37251676
[TBL] [Abstract][Full Text] [Related]
20. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial.
Rønn SH; Harsløf T; Oei L; Pedersen SB; Langdahl BL
Osteoporos Int; 2021 Jan; 32(1):185-191. PubMed ID: 33030563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
